175 related articles for article (PubMed ID: 36640753)
21. A Diverse Range of Cardiac Adverse Events Associated with Immune Checkpoint Inhibitor Therapy.
Murakata Y; Tajiri K
Intern Med; 2022 Jul; 61(14):2099-2100. PubMed ID: 35283387
[No Abstract] [Full Text] [Related]
22. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
Mahmood SS; Fradley MG; Cohen JV; Nohria A; Reynolds KL; Heinzerling LM; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Awadalla M; Hassan MZO; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Lawrence DP; Groarke JD; Neilan TG
J Am Coll Cardiol; 2018 Apr; 71(16):1755-1764. PubMed ID: 29567210
[TBL] [Abstract][Full Text] [Related]
23. Focal myocarditis associated with immune checkpoint inhibitor therapy.
Hayashizaki M; Omote K; Tsuneta S; Nagai T; Anzai T
Eur Heart J Cardiovasc Imaging; 2023 Nov; 24(12):e308. PubMed ID: 37694290
[No Abstract] [Full Text] [Related]
24. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
Fenioux C; Abbar B; Boussouar S; Bretagne M; Power JR; Moslehi JJ; Gougis P; Amelin D; Dechartres A; Lehmann LH; Courand PY; Cautela J; Alexandre J; Procureur A; Rozes A; Leonard-Louis S; Qin J; ; Cheynier R; Charmeteau-De Muylder B; Redheuil A; Tubach F; Cadranel J; Milon A; Ederhy S; Similowski T; Johnson DB; Pizzo I; Catalan T; Benveniste O; Hayek SS; Allenbach Y; Rosenzwajg M; Dolladille C; Salem JE
Nat Med; 2023 Dec; 29(12):3100-3110. PubMed ID: 37884625
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians.
Raschi E; Rossi S; De Giglio A; Fusaroli M; Burgazzi F; Rinaldi R; Potena L
Drug Saf; 2023 Sep; 46(9):819-833. PubMed ID: 37341925
[TBL] [Abstract][Full Text] [Related]
26. Routine assessment of cardiotoxicity in patients undergoing long-term immune checkpoint inhibitor therapy.
Tamura Y; Tamura Y; Yamada K; Taniguchi H; Iwasawa J; Yada H; Kawamura A
Heart Vessels; 2022 Nov; 37(11):1859-1865. PubMed ID: 35633369
[TBL] [Abstract][Full Text] [Related]
27. Risk Factors for Immune Checkpoint Inhibitor-Mediated Cardiovascular Toxicities.
Yousif LI; Screever EM; Versluis D; Aboumsallem JP; Nierkens S; Manintveld OC; de Boer RA; Meijers WC
Curr Oncol Rep; 2023 Jul; 25(7):753-763. PubMed ID: 37079251
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases.
Atallah-Yunes SA; Kadado AJ; Kaufman GP; Hernandez-Montfort J
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1527-1557. PubMed ID: 31028541
[TBL] [Abstract][Full Text] [Related]
29. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
[TBL] [Abstract][Full Text] [Related]
30. Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment.
Soman B; Dias MC; Rizvi SAJ; Kardos A
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593626
[TBL] [Abstract][Full Text] [Related]
31. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system.
Michel L; Totzeck M; Lehmann L; Finke D
Herz; 2020 Nov; 45(7):645-651. PubMed ID: 32533218
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease.
Leaver PJ; Jang HS; Vernon ST; Fernando SL
BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32404371
[TBL] [Abstract][Full Text] [Related]
33. Fatal association of fulminant myocarditis and rhabdomyolysis after immune checkpoint blockade.
Tomoaia R; Beyer RȘ; Pop D; Minciună IA; Dădârlat-Pop A
Eur J Cancer; 2020 Jun; 132():224-227. PubMed ID: 32336614
[No Abstract] [Full Text] [Related]
34. Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
Zhu H; Galdos FX; Lee D; Waliany S; Huang YV; Ryan J; Dang K; Neal JW; Wakelee HA; Reddy SA; Srinivas S; Lin LL; Witteles RM; Maecker HT; Davis MM; Nguyen PK; Wu SM
Circulation; 2022 Jul; 146(4):316-335. PubMed ID: 35762356
[TBL] [Abstract][Full Text] [Related]
35. Weighing Antitumor Immunity against Life-threatening Myocarditis from Immune-Checkpoint Inhibitors.
Dougan M
Cancer Discov; 2023 May; 13(5):1040-1042. PubMed ID: 37139724
[TBL] [Abstract][Full Text] [Related]
36. Why are immune adverse events so common with checkpoint inhibitor therapy?
Lyubchenko T; Leung DYM; Goleva E
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):608-610. PubMed ID: 33774187
[No Abstract] [Full Text] [Related]
37. Immune checkpoint inhibitor-associated myocarditis: from pathophysiology to rechallenge of therapy - a narrative review.
Tedeschi A; Camilli M; Ammirati E; Gentile P; Palazzini M; Conti N; Verde A; Masciocco G; Foti G; Giannattasio C; Garascia A
Future Cardiol; 2023 Feb; 19(2):91-103. PubMed ID: 37078438
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.
Zhu H; Ivanovic M; Nguyen A; Nguyen PK; Wu SM
J Mol Cell Cardiol; 2021 Nov; 160():121-127. PubMed ID: 34303670
[TBL] [Abstract][Full Text] [Related]
39. Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis.
Vasbinder A; Ismail A; Salem JE; Hayek SS
Curr Cardiol Rep; 2023 Sep; 25(9):959-967. PubMed ID: 37436648
[TBL] [Abstract][Full Text] [Related]
40. Unanticipated Myocarditis in a Surgical Patient Treated With Pembrolizumab: A Case Report.
Nierstedt RT; Yeahia R; Barnett KM
A A Pract; 2020 Apr; 14(6):e01177. PubMed ID: 32132361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
